Giving Standardized Estradiol Therapy in Transgender Women to Research Interactions with HIV Therapy: the GET IT RIgHT Study
Primary Objective
The purpose of this study is to determine the best combination of antiretroviral therapy for transgender women (TW) living with HIV who take feminization hormonal therapy (FHT). All participants will receive FHT. The study will determine if TW remain undetectable while receiving FHT for 48 weeks. Additionally, it will assess if hormone levels change based on the type of HIV medication taken.
Description
Transgender women (TW) are the fastest-growing group of people with HIV (PWH). Historically, TW have had few opportunities to participate in research, and often experience barriers to engaging in care. More research is needed to help providers when it comes to choosing HIV medication in TW on Feminizing Hormone Therapy (FHT).
Details
Locations
Outpatient CTRC
University of Colorado Hospital
Principal Investigator
Thomas Campbell
Resources
Study ID
Protocol Number: 23-1505
More information available at ClinicalTrials.gov: NCT06005610
Categories
Is this Study for You?
Not finding the right Study for you? Join ResearchMatch, a nation-wide registry connecting volunteers and researchers